Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Pharmacol ; 953: 175784, 2023 Aug 15.
Article in English | MEDLINE | ID: mdl-37179042

ABSTRACT

Alzheimer's disease (AD), as an advanced neurodegenerative disease, is characterized by the everlasting impairment of memory, which is determined by hyperphosphorylation of intracellular Tau protein and accumulation of beta-amyloid (Aß) in the extracellular space. Minocycline is an antioxidant with neuroprotective effects that can freely cross the blood-brain barrier (BBB). This study investigated the effect of minocycline on the changes in learning and memory functions, activities of blood serum antioxidant enzymes, neuronal loss, and the number of Aß plaques after AD induced by Aß in male rats. Healthy adult male Wistar rats (200-220g) were divided randomly into 11 groups (n = 10). The rats received minocycline (50 and 100 mg/kg/day; per os (P.O.)) before, after, and before/after AD induction for 30 days. At the end of the treatment course, behavioral performance was measured by standardized behavioral paradigms. Subsequently, brain samples and blood serum were collected for histological and biochemical analysis. The results indicated that Aß injection impaired learning and memory performances in the Morris water maze test, reduced exploratory/locomotor activities in the open field test, and enhanced anxiety-like behavior in the elevated plus maze. The behavioral deficits were accompanied by hippocampal oxidative stress (decreased glutathione (GSH) peroxidase enzyme activity and increased malondialdehyde (MDA) levels in the brain (hippocampus) tissue), increased number of Aß plaques, and neuronal loss in the hippocampus evidenced by Thioflavin S and H&E staining, respectively. Minocycline improved anxiety-like behavior, recovered Aß-induced learning and memory deficits, increased GSH and decreased MDA levels, and prevented neuronal loss and the accumulation of Aß plaques. Our results demonstrated that minocycline has neuroprotective effects and can reduce memory dysfunction, which are due to its antioxidant and anti-apoptotic effects.


Subject(s)
Alzheimer Disease , Neurodegenerative Diseases , Neuroprotective Agents , Rats , Male , Animals , Alzheimer Disease/chemically induced , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Minocycline/pharmacology , Minocycline/therapeutic use , Rats, Wistar , Antioxidants/pharmacology , Antioxidants/therapeutic use , Antioxidants/metabolism , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Neuroprotective Agents/metabolism , Neurodegenerative Diseases/metabolism , Disease Models, Animal , Maze Learning , Hippocampus , Memory Disorders/chemically induced , Memory Disorders/drug therapy , Memory Disorders/metabolism
2.
J Chem Neuroanat ; 125: 102158, 2022 11.
Article in English | MEDLINE | ID: mdl-36084891

ABSTRACT

OBJECTIVES: Minocycline hydrochloride is a semi-synthetic, second-generation tetracycline with neuroprotective, neurorestorative, anti-amyloidogenic, anti-inflammatory, antioxidant, and anti-apoptotic properties. The present study was designed to investigate the potential protective effects of minocycline against beta-amyloid (Aß)-induced Alzheimer's disease (AD), recognition memory decline, and the possible involved anti-apoptotic mechanisms. METHODS: The rats were treated with minocycline (50 and 100 mg/kg/day; P.O.) after AD induction for 30 days. Behavioral functions were assessed by employing standard behavioral tests, including novel object recognition (NOR) and passive avoidance learning (PAL) tasks. Then, total antioxidant capacity (TAC) and total oxidant status (TOS) were measured in blood serum using ELISA kits. Apoptosis and the number of Aß plaques were examined by the TUNEL and Congo red staining, respectively. RESULTS: Treatment of Aß rats with minocycline improved memory deficit in the PAL task and a decline in recognition memory in the NOR test. Minocycline at 50 and 100 mg/kg significantly reduced the TOS levels and increased the TAC levels (P < 0.0001). Also, minocycline at 50 and 100 mg/kg reduced the apoptotic index in the hippocampus of Aß rats. After Congo red staining, the minocycline group showed improved cell morphology and markedly fewer Aß plaques. CONCLUSIONS: Minocycline reduced memory and learning deficit in behavioral experiments after Aß injection, which may be due to its anti-inflammatory and anti-apoptotic effects.


Subject(s)
Alzheimer Disease , Amyloid beta-Peptides , Rats , Animals , Male , Amyloid beta-Peptides/metabolism , Minocycline/pharmacology , Minocycline/therapeutic use , Antioxidants/pharmacology , Congo Red/pharmacology , Hippocampus/metabolism , Alzheimer Disease/chemically induced , Alzheimer Disease/drug therapy , Plaque, Amyloid , Avoidance Learning , Anti-Inflammatory Agents/pharmacology , Disease Models, Animal , Peptide Fragments/pharmacology
3.
BMC Nephrol ; 22(1): 228, 2021 06 18.
Article in English | MEDLINE | ID: mdl-34144690

ABSTRACT

BACKGROUND: Silver nanoparticles (AgNPs) can accumulate in various organs after oral exposure. The main objective of the current study is to evaluate the renal toxicity induced by AgNPs after repeated oral exposure and to determine the relevant molecular mechanisms. METHODS: In this study, 40 male Wistar rats were treated with solutions containing 30, 125, 300, and 700 mg/kg of AgNPs. After 28 days of exposure, histopathological changes were assessed using hematoxylin-eosin (H&E), Masson's trichrome, and periodic acid-Schiff (PAS) staining. Apoptosis was quantified by TUNEL and immunohistochemistry of caspase-3, and the level of expression of the mRNAs of growth factors was determined using RT-PCR. RESULTS: Histopathologic examination revealed degenerative changes in the glomeruli, loss of tubular architecture, loss of brush border, and interrupted tubular basal laminae. These changes were more noticeable in groups treated with 30 and 125 mg/kg. The collagen intensity increased in the group treated with 30 mg/kg in both the cortex and the medulla. Apoptosis was much more evident in middle-dose groups (i.e., 125 and 300 mg/kg). The results of RT-PCR indicated that Bcl-2 and Bax mRNAs upregulated in the treated groups (p < 0.05). Moreover, the data related to EGF, TNF-α, and TGF-ß1 revealed that AgNPs induced significant changes in gene expression in the groups treated with 30 and 700 mg/kg compared to the control group. CONCLUSION: Our observations showed that AgNPs played a critical role in in vivo renal toxicity.


Subject(s)
Chemical and Drug Induced Liver Injury/etiology , Metal Nanoparticles/toxicity , Animals , Apoptosis/genetics , Blood Urea Nitrogen , Body Weight/drug effects , Caspase 3/metabolism , Chemical and Drug Induced Liver Injury/pathology , Creatinine/blood , Epidermal Growth Factor/genetics , Extracellular Matrix Proteins/genetics , Gene Expression , Immunohistochemistry , In Situ Nick-End Labeling , Kidney/drug effects , Kidney/pathology , Male , Organ Size/drug effects , RNA, Messenger/genetics , Rats, Wistar , Transforming Growth Factor beta/genetics , Tumor Necrosis Factor-alpha/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...